Compare Stocks: ITOS, TSHA, SEPN, and RXRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ITOS iTeos Therapeutics	$10.15	$10.14	$6.18 ▼ $11.35	$448.73M	1.31	1.57 million shs	N/A
RXRX Recursion Pharmaceuticals	$3.29 -1.8%	$3.30	$2.77 ▼ $7.18	$1.74B	1.03	18.27 million shs	7.22 million shs
SEPN Septerna	$47.81 +0.1%	$34.94	$10.74 ▼ $51.10	$2.16B	2.29	354,899 shs	778,014 shs
TSHA Taysha Gene Therapies	$6.28 -6.0%	$6.08	$2.71 ▼ $7.30	$1.80B	1.22	2.88 million shs	2.10 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ITOS iTeos Therapeutics	0.00%	0.00%	0.00%	0.00%	+0.40%
RXRX Recursion Pharmaceuticals	+1.82%	+1.21%	-5.90%	+9.84%	-36.67%
SEPN Septerna	+22.93%	+22.52%	+32.93%	+92.97%	+315.67%
TSHA Taysha Gene Therapies	+4.87%	+7.74%	+5.36%	+0.15%	+142.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ITOS iTeos Therapeutics	$10.15	$10.14	$6.18 ▼ $11.35	$448.73M	1.31	1.57 million shs	N/A
RXRX Recursion Pharmaceuticals	$3.29 -1.8%	$3.30	$2.77 ▼ $7.18	$1.74B	1.03	18.27 million shs	7.22 million shs
SEPN Septerna	$47.81 +0.1%	$34.94	$10.74 ▼ $51.10	$2.16B	2.29	354,899 shs	778,014 shs
TSHA Taysha Gene Therapies	$6.28 -6.0%	$6.08	$2.71 ▼ $7.30	$1.80B	1.22	2.88 million shs	2.10 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ITOS iTeos Therapeutics	0.00%	0.00%	0.00%	0.00%	+0.40%
RXRX Recursion Pharmaceuticals	+1.82%	+1.21%	-5.90%	+9.84%	-36.67%
SEPN Septerna	+22.93%	+22.52%	+32.93%	+92.97%	+315.67%
TSHA Taysha Gene Therapies	+4.87%	+7.74%	+5.36%	+0.15%	+142.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ITOS iTeos Therapeutics	0.00	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.10	146.20% Upside
SEPN Septerna	2.82	Moderate Buy	$49.22	2.95% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	103.33% Upside

Current Analyst Ratings Breakdown

Latest ITOS, TSHA, SEPN, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	SEPN Septerna	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $50.00
8/12/2026	SEPN Septerna	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $60.00
8/11/2026	SEPN Septerna	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$49.00
8/11/2026	SEPN Septerna	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
8/11/2026	SEPN Septerna	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $51.00
7/21/2026	TSHA Taysha Gene Therapies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $13.00
7/17/2026	RXRX Recursion Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SEPN Septerna	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	TSHA Taysha Gene Therapies	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$11.00
7/1/2026	SEPN Septerna	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$52.00 ➝ $45.00
7/1/2026	SEPN Septerna	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $43.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ITOS iTeos Therapeutics	$35M	12.82	N/A	N/A	$11.17 per share	0.91
RXRX Recursion Pharmaceuticals	$53.94M	32.32	N/A	N/A	$1.73 per share	1.90
SEPN Septerna	$98.88M	21.79	N/A	N/A	$8.53 per share	5.60
TSHA Taysha Gene Therapies	$7.47M	241.55	N/A	N/A	$0.90 per share	6.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ITOS iTeos Therapeutics	-$134.41M	-$4.67	N/A	N/A	N/A	N/A	-33.26%	-28.16%	N/A
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	N/A
SEPN Septerna	-$48.88M	-$0.54	N/A	N/A	N/A	-24.51%	-9.59%	-6.22%	N/A
TSHA Taysha Gene Therapies	-$109M	-$0.38	N/A	N/A	N/A	N/A	-56.07%	-40.16%	N/A

Latest ITOS, TSHA, SEPN, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	-$0.29	+$0.1360	-$0.29	$19.22 million	$26.75 million
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ITOS iTeos Therapeutics	N/A	7.53	7.53
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03
SEPN Septerna	N/A	4.71	4.71
TSHA Taysha Gene Therapies	0.23	14.04	14.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ITOS iTeos Therapeutics	97.16%
RXRX Recursion Pharmaceuticals	89.06%
SEPN Septerna	N/A
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
ITOS iTeos Therapeutics	14.20%
RXRX Recursion Pharmaceuticals	6.65%
SEPN Septerna	5.80%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ITOS iTeos Therapeutics	90	44.21 million	37.93 million	Optionable
RXRX Recursion Pharmaceuticals	400	529.91 million	494.67 million	Optionable
SEPN Septerna	N/A	45.08 million	42.46 million	N/A
TSHA Taysha Gene Therapies	180	287.36 million	277.36 million	Optionable

ITOS, TSHA, SEPN, and RXRX Headlines

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings

4 hours ago | marketbeat.com

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

August 12 at 4:23 AM | marketbeat.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11 at 10:00 PM | seekingalpha.com

Taysha Gene Therapies Q2 Earnings Call Highlights

August 11 at 9:03 PM | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

August 11 at 4:10 PM | marketbeat.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11 at 4:00 PM | globenewswire.com

Taysha Gene Therapies (TSHA) Expected to Post Quarterly Earnings on Tuesday

August 10 at 1:56 AM | americanbankingnews.com

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 4, 2026 | globenewswire.com

Taysha Gene Therapies (TSHA) to Announce Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Taysha Taps Catalent for Potential Commercial Manufacturing of TSHA-102

August 3, 2026 | finance.yahoo.com

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

August 3, 2026 | globenewswire.com

Seven Fleet Capital Management LP Has $2.80 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

August 2, 2026 | marketbeat.com

ADAR1 Capital Management LLC Has $13.32 Million Stock Position in Taysha Gene Therapies, Inc. $TSHA

July 29, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Healthcare of Ontario Pension Plan Trust Fund

July 28, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading 8% Higher - Still a Buy?

July 27, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. $TSHA Shares Acquired by Rice Hall James & Associates LLC

July 26, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. $TSHA Position Reduced by Affinity Asset Advisors LLC

July 25, 2026 | marketbeat.com

Siren L.L.C. Sells 1,300,000 Shares of Taysha Gene Therapies, Inc. $TSHA

July 24, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of "Buy" by Brokerages

July 24, 2026 | marketbeat.com

Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In

July 15, 2026 | finance.yahoo.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 7.4% - Still a Buy?

July 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITOS, TSHA, SEPN, and RXRX Company Descriptions

iTeos Therapeutics NASDAQ:ITOS

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.29 -0.06 (-1.79%)

As of 02:27 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Septerna NASDAQ:SEPN

$47.81 +0.05 (+0.10%)

As of 02:29 PM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

Taysha Gene Therapies NASDAQ:TSHA

$6.28 -0.40 (-5.99%)

As of 02:28 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ITOS, TSHA, SEPN, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ITOS, TSHA, SEPN, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ITOS, TSHA, SEPN, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITOS, TSHA, SEPN, and RXRX Company Descriptions

iTeos Therapeutics NASDAQ:ITOS

Recursion Pharmaceuticals NASDAQ:RXRX

Septerna NASDAQ:SEPN

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ITOS, TSHA, SEPN, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ITOS, TSHA, SEPN, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ITOS, TSHA, SEPN, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITOS, TSHA, SEPN, and RXRX Company Descriptions

iTeos Therapeutics NASDAQ:ITOS

Recursion Pharmaceuticals NASDAQ:RXRX

Septerna NASDAQ:SEPN

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools